The high-risk group (around 35% survival at 5 years) comprises all cases MYCN-amplified neuroblastoma regardless of stage and age, plus non-MYCN-amplified stage 4 tumors in children ≥18 months old. The gene discussed is MYCN; the disease is neuroblastoma.